Lord, Abbett & Co. LLC Beam Therapeutics Inc. Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$29.86 - $62.36 $469,548 - $980,611	15,725 Added 24.35%	80,294 $3.11 Million
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $13,862 - $21,197	258 Added 0.4%	64,569 $3.7 Million
Q4 2021 Feb 11, 2022	SELL	$68.02 - $99.06 $52,443 - $76,375	-771 Reduced 1.18%	64,311 $5.13 Million
Q3 2021 Nov 09, 2021	SELL	$84.37 - $133.6 $89,432 - $141,616	-1,060 Reduced 1.6%	65,082 $5.66 Million
Q2 2021 Aug 11, 2021	SELL	$64.12 - $128.71 $404,148 - $811,259	-6,303 Reduced 8.7%	66,142 $8.51 Million
Q1 2021 May 11, 2021	SELL	$71.28 - $120.75 $6.99 Million - $11.8 Million	-98,027 Reduced 57.5%	72,445 $5.8 Million
Q4 2020 Feb 09, 2021	SELL	$22.24 - $95.63 $115,692 - $497,467	-5,202 Reduced 2.96%	170,472 $13.9 Million
Q3 2020 Nov 12, 2020	BUY	$19.0 - $30.57 $3.34 Million - $5.37 Million	175,674 New	175,674 $4.33 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.